Table 3. The diagnostic and prognostic value of PLR in PCa.
| Inflammation -related indicators | Study design | Year | Study participants (number) | Effects/results | Major study limitations | References |
|---|---|---|---|---|---|---|
| PLR | Clinical trial | 2021 | Serum PSA levels of ≥3.0 ng/mL or abnormal DRE findings patients (n=1,652) | The pre-biopsy PLR is not an independent predictor of CSPCa at the prostate biopsy | Non-randomized design, unique racial population | (43) |
| PLR | Clinical trial | 2015 | prostate biopsy patients (n=873) | PLR was found to be the additional predictor of prostatic carcinoma | Not available | (44) |
| PLR | Meta-analysis | 2018 | 7,228 patients from 18 studies | Elevated NLR and PLR was associated with poor oncologic outcomes | Not available | (45) |
| PLR | Meta-analysis | 2018 | 1,324 patients from 6 studies | High PLR was correlated with poor DFS and OS in patients with PCa | Not available | (46) |
| PLR | Clinical trial | 2016 | PCa patients (n=290) | PLR might play a significant role in the prognosis of PCa patients treated with ADT | Retrospective investigation, single institution | (47) |
| PLR | Clinical trial | 2018 | PCa patients (n=226) | The pretreatment NLR and PLR might be beneficial to predict the progression and prognosis of PCa | Erroneous data collection, small subject number | (48) |
PLR, platelet-to-lymphocyte-count ratio; PCa, prostate cancer; CSPCa, clinically insignificant prostate cancer; NLR, neutrophil-to-lymphocyte-count ratio; DFS, disease-free survival; ADT, androgen deprivation therapy.